---
title: "MoonLake Immunotherapeutics prices $200M public offering of Class A shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290648265.md"
description: "MoonLake Immunotherapeutics (MLTX) has priced an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share, alongside pre-funded warrants for up to 1 million additional shares. The biotechnology company aims to raise capital to fund its operations and development programs."
datetime: "2026-06-24T05:43:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290648265.md)
  - [en](https://longbridge.com/en/news/290648265.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290648265.md)
---

# MoonLake Immunotherapeutics prices $200M public offering of Class A shares

MoonLake Immunotherapeutics (MLTX) said it has priced an underwritten public offering of 9M Class A ordinary shares at $20.00 per share, along with pre-funded warrants to purchase up to 1M additional shares, as the biotechnology company seeks to raise capital for its operations and development programs. The pre-funded warrants are exercisable immed...

### Related Stocks

- [MLTX.US](https://longbridge.com/en/quote/MLTX.US.md)

## Related News & Research

- [MoonLake Immunotherapeutics CSO Kristian Reich disposes of $1 million in common shares](https://longbridge.com/en/news/293660700.md)
- [MoonLake Immunotherapeutics CSO Kristian Reich sells 43,700 shares for $877,933](https://longbridge.com/en/news/293391282.md)
- [Hess Midstream raises quarterly distribution to $0.79 per Class A share](https://longbridge.com/en/news/293970471.md)
- [Zhihu files HKEX next-day disclosure return reporting 371,436 Class B-to-A share conversions](https://longbridge.com/en/news/294059412.md)
- [Bollard Group LLC Reduces Position in Aclaris Therapeutics, Inc. $ACRS](https://longbridge.com/en/news/293815783.md)